Life Sciences Scoop | June 2024

Warman O'Brien

Global Life Sciences Recruitment Partner across the USA, UK, Europe and APAC

Published Jun 4, 2024

Can you believe it's summer already? Time flies in the world of Life Sciences, with so many exciting clinical trials announced over the past month! While some things change, our dedication to keeping you informed with the latest industry news and jobs remains constant. Even with holidays approaching, we can't let you miss out on some exciting career opportunities.

This month's newsletter brings you:

🟠 Latest jobs within #Biostatistics #StatisticalProgramming #Medical #Scientific and #ClinicalData#Management

🟠 Tips for staying grounded during conference season

🟠 How to get a feel for company culture during the interview

🟠 Clinical trial news: Psychiatric Disorders & Breast Cancer therapies

🟠 Free CV guide for Life Sciences professionals, carefully crafted by our team

You can subscribe to our monthly newsletter and get it straight to your inbox, to make sure you don't miss it.

✉️ Click here to subscribe to the mailer ✉️

Download your free CV guide

While every CV is unique in how you market yourself, a strong CV for Life Sciences roles will generally follow a similar structure. To help you get started, we've created a CV template with suggestions from our team. This will give you an overview of what a good Life Sciences candidate CV should look like.

In this guide, you'll learn:

🟠 The best CV structure for the Life Sciences talent

🟠 What to include in the CV summary

🟠 How to convert your responsibilities into achievements

Click here to download your free guide now and let your CV speak for itself!

Highlights from the PharmaSUG Conference in Baltimore

Our team had a fantastic time exhibiting at the PharmaSUG Conference in vibrant Baltimore last month. We were thrilled to meet so many of you who visited our booth and tried your luck at the Blazepod challenge. Hope to see you all again next year!

Haven't had a chance to connect with our team yet? Feel free to drop them a message for a confidential chat.

Michael Woodhead (✉️ mike@warmanobrien.com)

Josh Forbes (✉️ josh@warmanobrien.com)

Jobs of the month

What to read

Recruitment Tips | How to stay grounded as a Medical Affairs professional during conference season

With conference season in full swing, many professionals, like Medical Science Liaisons, find themselves constantly on the move. This exciting opportunity to travel can also present challenges in maintaining a routine and prioritising mental health.

Camilla Fedi , our Senior Consultant in Medical Affairs, put together some key strategies to stay grounded while traveling extensively:

Sleep Rituals: Even if you struggle to sleep at home, try to stick to a consistent sleep schedule when traveling. Develop a relaxing bedtime routine (like reading or meditation) to wind down. Extra tip: Invest in good earplugs and a sleep mask to block out distractions on planes. If you use the Alexa app, you can use voice commands like "Alexa, help me sleep" to start a relaxing meditation session.
Stay Connected: Schedule dedicated video calls with family and friends to combat feelings of isolation. Catch up with loved ones during downtime at the airport.
Establish Boundaries: Setting boundaries between work and personal life is crucial. Designate specific times to check emails and avoid the temptation to work late. Consider turning off phone notifications after a certain time to truly switch off after work.
Pack Smart Snacks: Airport food options can be limited and unhealthy. Pack healthy snacks to maintain your energy levels and avoid overpriced airport fare. Your body and mind will thank you!
Maintain Physical Fitness: Hotel gyms may not be appealing to everyone. Pack resistance bands or find a quick bodyweight routine to maintain some physical fitness. Even simple stretches can be extremely beneficial when traveling frequently.

Recruitment Tips | How to get a feel for the company culture during your recruitment process

Finding your dream role isn't just about landing a job; it's about aligning yourself with a company culture that ignites your passions and fuels your daily grind. Imagine an environment that sparks inspiration, fosters engagement, and transforms your workday into a wellspring of fulfillment.

While uncovering a company's true spirit before signing on the dotted line can be a challenge, it's not an impossible feat. With a dash of keen observation, insightful questions, and dedicated research, you can gain valuable intel.

Here, Kay Wilson , our HR Business Partner, shares some tactics to utilise during the interview process, helping you cultivate a deeper understanding of an organisation's cultural landscape.

🔗 CLICK HERE to read more 🔗

Clinical Trial Updates | AbbVie, Gilgamesh Sign Potential $2B Deal to Develop Neuroplastogens for Psychiatric Disorders

AbbVie is investing heavily ($2 billion) in a collaboration with Gilgamesh Pharmaceuticals to develop next-generation psychedelic therapies for mental health conditions. These "neuroplasticgens" aim to offer the benefits of psychedelics (treating anxiety and depression) with fewer side effects (like hallucinations).

This deal highlights the growing interest in psychedelics for treating mental health, with AbbVie joining other pharma companies like Reunion Neuroscience and MindMed in exploring this area.

🔗 CLICK HERE to read more 🔗

Clinical Trial Updates | Teva and Medincell report positive data for TEV-‘749 in Schizophrenia trial

Schizophrenia imposes a significant burden on both individuals and society in the United States, with approximately 3.5 million people currently diagnosed. This chronic and severely debilitating mental disorder not only affects individuals' quality of life but also places substantial economic strain due to healthcare costs.

The Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) aimed to address the unmet needs of individuals with schizophrenia.

TEV-'749, a novel once-monthly subcutaneous injection, was evaluated for its potential to alleviate symptoms and enhance treatment adherence. Its innovative delivery system, SteadyTeq™ technology, offers controlled release of olanzapine, a well-established antipsychotic medication.Encouragingly, the SOLARIS trial demonstrated promising results.

Across all dosage groups, TEV-'749 exhibited statistically significant reductions in schizophrenia symptom severity compared to placebo, as measured by the Positive and Negative Syndrome Scale (PANSS) total score. Moreover, TEV-'749 was well-tolerated, with no incidence of post-injection delirium/sedation syndrome (PDSS) observed. Secondary endpoints, including measures of global clinical impression and social functioning, also showed favorable outcomes.

These findings suggest TEV-'749 may offer an effective and convenient treatment option for individuals with schizophrenia, potentially alleviating the substantial burden associated with this complex disorder.

🔗 CLICK HERE to read more 🔗

Clinical Trial Updates | FDA Decision News

The FDA has granted a priority review for Roche's inavolisib, in combination with fulvestrant and Pfizer’s Ibrance (palbociclib), for treating PIK3CA-mutated, HR-positive, HER2-negative breast cancer. This decision sets a date of 27 November for the FDA to evaluate the therapy.

The therapy targets adult patients with locally advanced or metastatic breast cancer, especially those experiencing recurrence within 12 months of adjuvant endocrine treatment. Inavolisib, an oral PI3 kinase inhibitor, disrupts PI3K/Akt/mTOR pathway signaling, crucial for cell growth and survival. It also recently received breakthrough therapy designation.The priority review is based on promising results from the Phase III INAVO120 trial, where the combination therapy showed a progression-free survival of 15 months compared to 7.3 months with the standard fulvestrant and Ibrance regimen.

Roche is also pursuing regulatory approval in other regions, including with the European Medicines Agency. More detailed data will be presented at the upcoming ASCO Annual Meeting in Chicago from 31 May to 4 June. In other FDA news, Eli Lilly and Company have secured accelerated approval for Retevmo, their treatment for pediatric cancers.

🔗 CLICK HERE to read more 🔗

Who are Warman O’Brien?

Warman O'Brien is a Global Life Sciences Recruitment partner. We're proud to say that we have a 90% success rate of CV-to-interview matches, and our partnerships with pioneering Biotech, Pharma, and CROs across the USA, Canada, UK, and Europe.

We recruit top talent across multiple functional areas, including Biometrics, Data Science, Quality Assurance, Regulatory Affairs, Clinical Research, Discovery Sciences, and Medical.

Subscribe to our newsletter and be the first to apply for the new job offerings.